Haemonetics Corporation

HAE Healthcare Medical Devices

Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.

Revenue
+9.30%
EPS
+25.9%
Free cash flow
+20.4%
Total debt
+21.0%

Quarter to September 2026, against a year earlier

119.97 4.14 −3.34%
Market cap
$5.7B
P/E
54.5×
Fwd P/E
30.2×
Dividend yield
—
F-score
6/9
Altman Z
2.21
Beneish M
−2.81
Dividend safety
n/a

Haemonetics Corporation (HAE) EV/FCF

Alert me on EV/FCF

As of 5 November 2026, Haemonetics Corporation (HAE) trades at a EV/FCF of 20.9×. Over the past ten years it has ranged from −195× (November 2015) to 3,721× (March 2016); the current reading is higher than 18% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2026 13.9× (39.70%)
FY2025 23.0× (31.95%)
FY2024 33.8× (39.68%)
FY2023 56.1× 23.62%
FY2022 45.3× (45.52%)
FY2021 83.2× 101.30%
FY2020 41.4× (62.67%)
FY2019 111× 345.72%
FY2018 24.9× (2.56%)
FY2017 25.5× (74.75%)

Quarterly newest first

Period EV/FCF Change
Sep 2026 18.2× 22.78%
Jun 2026 14.9× 7.11%
Mar 2026 13.9× 0.32%
Dec 2025 13.8× 21.80%
43 more quarters

Against its own ten years

Low −195× High 3,721×
Ten-year median 40.2×
Current reading's percentile 13

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on HAE